Cargando…

The clinical significance of CXCL16 in the treatment of advanced non‐small cell lung cancer

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF)‐A, has shown efficacy in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC). There are no identified or clinically validated biomarkers to determine the efficacy of bevacizumab. In thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shibata, Yuji, Kobayashi, Nobuaki, Sato, Takashi, Nakashima, Kentaro, Kaneko, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180569/ https://www.ncbi.nlm.nih.gov/pubmed/32163231 http://dx.doi.org/10.1111/1759-7714.13387

Ejemplares similares

The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis
por: Horita, Nobuyuki, et al.
Publicado: (2017)

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
por: Horita, Nobuyuki, et al.
Publicado: (2016)

The clinical significance of CXCL5 in non-small cell lung cancer
por: Wu, Kongju, et al.
Publicado: (2017)

Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma
por: SINGH, RAJESH, et al.
Publicado: (2014)

Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Regulatory role of heme oxygenase-1 in silica-induced lung injury
por: Nakashima, Kentaro, et al.
Publicado: (2018)

Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient
por: Matsumoto, Sachiko, et al.
Publicado: (2020)

Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival
por: Hald, Sigurd M., et al.
Publicado: (2015)

HbA1c level cannot predict the treatment outcome of smear-positive non-multi-drug-resistant HIV-negative pulmonary tuberculosis inpatients
por: Tashiro, Ken, et al.
Publicado: (2017)

Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
por: Katakura, Seigo, et al.
Publicado: (2019)

Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival
por: Hald, Sigurd M., et al.
Publicado: (2016)

Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer
por: Chen, Hao, et al.
Publicado: (2020)

Factors for Predicting Outcomes among Non-HIV Patients with Pulmonary Tuberculosis
por: Tsukahara, Toshinori, et al.
Publicado: (2017)

Unusual lung involvements of invasive mucinous adenocarcinoma with chylothorax
por: Aoki, Ayako, et al.
Publicado: (2020)

Association between CXCL16/CXCR6 expression and the clinicopathological features of patients with non-small cell lung cancer
por: Ke, Chuangwu, et al.
Publicado: (2017)

CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer
por: Zajkowska, Monika, et al.
Publicado: (2023)

The perioperative time course and clinical significance of the chemokine CXCL16 in patients undergoing cardiac surgery
por: Dreymueller, Daniela, et al.
Publicado: (2015)

Prognostic Value of CXCL12 in Non-Small Cell Lung Cancer Patients Undergoing Tumor Resection
por: Kogue, Yurie, et al.
Publicado: (2023)

Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non‐small cell lung cancer
por: Wakabayashi, Yu, et al.
Publicado: (2020)

Advanced non-small cell lung cancer associated with hemophagocytic syndrome in a cachectic patient
por: Asai, Nobuhiro, et al.
Publicado: (2012)

Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer
por: Teranishi, Shuhei, et al.
Publicado: (2020)

Nasally Administered Lactococcus lactis Secreting Heme Oxygenase-1 Attenuates Murine Emphysema
por: Yumoto, Kentaro, et al.
Publicado: (2020)

Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma
por: Hirama, Nobuyuki, et al.
Publicado: (2023)

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
por: Sakurai, Reiko, et al.
Publicado: (2020)

Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib
por: Teranishi, Shuhei, et al.
Publicado: (2022)

The Platelet Count Can Predict In-hospital Death in HIV-negative Smear-positive Pulmonary Tuberculosis Inpatients
por: Goto, Hideto, et al.
Publicado: (2018)

Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy
por: Matsukane, Ryosuke, et al.
Publicado: (2021)

Diagnostic and Prognostic Significances of MUC5B and TTF-1 Expressions in Resected Non-Small Cell Lung Cancer
por: Nagashio, Ryo, et al.
Publicado: (2015)

The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes
por: Kobayashi, Nobuaki, et al.
Publicado: (2023)

Sensitivity and specificity of Cobas TaqMan MTB real-time polymerase chain reaction for culture-proven Mycobacterium tuberculosis: meta-analysis of 26999 specimens from 17 Studies
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Effect of coexisting advanced extrapulmonary solid cancer on progression of Mycobacterium avium complex lung disease
por: Inoue, Rei, et al.
Publicado: (2021)

Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis
por: Rabquer, Bradley J, et al.
Publicado: (2011)

CXCR4/CXCL12 in Non-Small-Cell Lung Cancer Metastasis to the Brain
por: Cavallaro, Sebastiano
Publicado: (2013)

Best regimens for treating chemo‐naïve incurable squamous non‐small cell lung cancer with a programmed death‐ligand 1 tumor proportion score of 1%–49%: A network meta‐analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
por: Isobe, Kazutoshi, et al.
Publicado: (2014)

Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma
por: JIANG, AIGUI, et al.
Publicado: (2013)

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
por: Kobayashi, Nobuaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0q2hnkq51cclg4bi96hj9bp9bp